Lantheus touts new study on contrast echocardiography
Lantheus Medical Imaging parent company Lantheus Holdings announced the results...Read more on AuntMinnie.comRelated Reading: Lantheus appoints new CCO Lantheus hires former Bayer director as new CMO Lantheus, CarThera partner on ultrasound cancer therapy Lantheus posts lower Q3 results Lantheus to acquire Progenics
Conclusion: Melanin-cored and doxorubicin-loaded perfluoropentane nanodroplets hold great promise for translational sono-chemo-photothermal cancer therapy.
Conclusion: The study revealed that ultrasound-guided celiac plexus neurolysis is more durable, tolerable, effective and safe compared to fluoroscopy-guided neurolysis of patient suffering from pancreatic cancer pain.
Herein, a hybrid redox responsive metal organic famework (MOF) nanoparticle based on Fe/Cu and disulfide bond for smart and robust tumor imaging and treatment is reported. The potential of this multifunctional MOF acts as a ferroptosis inducer, perfluoropentane (PFP) carrier, photothermal photosensitizer, and a bimodal imaging agent to guide cancer therapy. AbstractFerroptosis is attracting significant attention due to its effectiveness in tumor treatment. The efficiency to produce toxic lipid peroxides (LPOs) at the tumor site plays a key role in ferroptosis. A hybrid PFP@Fe/Cu ‐SS metal organic framework (MOF) is synth...
Conclusion: We developed and showed the therapeutic functions of a novel nanosystem with the combination of multiple theranostic nanoplatforms that can be triggered and activated by 808 nm NIR laser and US.
In this study, we scrutinized synthesis and characterization of a polypyrrole-coated multi-walled carbon nanotubes composite (PPy@MWCNTs). PPy@MWCNTs can absorb ultrasound irradiation by both of its components, and it was introduced as a new sonosensitizer.
Ultrasound (US) is an important imaging modality in brachytherapy (BT). In particular for low-dose-rate (LDR) and high-dose-rate (HDR) prostate implants transrectal ultrasound (TRUS) is widespread. Besides the common use of US for prostate implants, US can also be applied in gynecological and anal cancer therapies as examples amongst others.
This study sought to evaluate the prevalence of menopausal symptoms in a population of reproductive-aged women remote from cancer therapy compared with a group of healthy similar-aged controls and with a cohort of late reproductive-aged (LR) controls.MethodsParticipants were assessed for symptoms of menopause, early follicular phase hormones, and ultrasound examinations. Menopausal symptoms were analyzed in exposed participants and controls usingχ2 analyses, Wilcoxon-Mann Whitney tests, and multivariable logistic regression models.ResultsOne hundred seventy cancer survivors, 135 similar-aged controls, and 71 LR control...
Lantheus Medical Imaging parent Lantheus Holdings has announced the ongoing...Read more on AuntMinnie.comRelated Reading: Lantheus reports revenue increases for Q4, 2019 Lantheus touts new study on contrast echocardiography Lantheus appoints new CCO Lantheus hires former Bayer director as new CMO Lantheus, CarThera partner on ultrasound cancer therapy
In this study, we first found that Low-intensity ultrasound (LIUS) was capable of reducing the CSC populations in the xenograft model with ovarian cancer, with blocking survival, anti-apoptosis, self-renewal, and downregulating the cancer stemness genes in ovarian CSCs. Moreover, LIUS ameliorated IL-6/STAT3 inflammatory pathway via inhibiting IL-6-induced STAT3 phosphorylation, DNA binding activity and, the expressions of its downstream effectors in ovarian CSCs while no explicit effect was found in the corresponding bulk cancer cells. Additional approaches in molecular studies showed that LIUS disrupts CSC features via in...